SubsidieMeestersBenchmarking AI to predict mutagenicity by combing chemical structure and genome-wide mutation data
MUTAPREDICT is an AI-driven platform that predicts the mutagenic potential of new drugs using whole genome sequencing, enhancing safety assessments while reducing reliance on animal testing.
Projectdetails
Introduction
Assessing mutagenicity, the capacity of a substance to cause permanent and potentially harmful changes to an organism's DNA, is a pivotal concern in drug development. This assessment is crucial because it helps to predict the carcinogenic potential of new pharmaceuticals, ensuring that they are safe for human use.
Importance of Evaluating Mutagenicity
The importance of evaluating mutagenicity in drug development cannot be overstated. Drugs are designed to interact with biological systems to treat or prevent diseases, but they must do so without causing harmful genetic alterations.
Drug Development Process
The process of developing a new drug involves a complex, time-consuming, and costly sequence of research and testing to ensure efficacy and safety. If mutagenicity is not accurately assessed, the consequences can be severe.
Innovative Approaches
Addressing the complexities and limitations associated with assessing mutagenicity in drug development, an innovative approach utilizing artificial intelligence (AI) and whole genome sequencing (WGS) data presents a promising solution.
MUTAPREDICT Platform
MUTAPREDICT introduces an innovative AI-driven platform designed to revolutionize the field of drug development by accurately predicting the mutagenic potential of new chemical compounds.
Benefits of the Platform
This platform is set to address the ethical, economic, and temporal challenges associated with conventional animal testing and in vitro analyses, promoting a more humane, cost-effective, and efficient approach to drug safety assessments.
Accelerating Drug Development
Leveraging advanced WGS data, our solution significantly accelerates the drug development process, ensuring both safety and efficacy.
Value Proposition
Our value proposition encompasses ethical and sustainable drug development by offering a viable alternative to animal testing, thus meeting the growing demands for ethical research practices.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-10-2024 |
| Einddatum | 31-3-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
dAta-dRiven integrated approaches to CHemIcal safety assessMEnt and Drug dEvelopmentThe ARCHIMEDES project aims to revolutionize chemical and drug development by integrating toxicogenomics, AI, and a Knowledge Graph to enhance safety and innovation in a regulatory-compliant manner. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistanceAI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance. | ERC Synergy ... | € 10.968.734 | 2025 | Details |
Genetically anchored drug target discovery for neglected diseasesGenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases. | ERC Starting... | € 1.498.089 | 2024 | Details |
Developing a human-based stem cell model for reproductive toxicityDeveloping a high-throughput human-based assay for male reproductive toxicity to enhance drug safety testing and reduce reliance on animal models. | ERC Proof of... | € 150.000 | 2024 | Details |
Revolutionizing AI in drug discovery via innovative molecular representation paradigmsReMINDER aims to revolutionize drug discovery by developing novel molecular representations for AI, enhancing model capabilities and solving complex chemical challenges. | ERC Starting... | € 1.494.006 | 2023 | Details |
dAta-dRiven integrated approaches to CHemIcal safety assessMEnt and Drug dEvelopment
The ARCHIMEDES project aims to revolutionize chemical and drug development by integrating toxicogenomics, AI, and a Knowledge Graph to enhance safety and innovation in a regulatory-compliant manner.
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance
AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.
Genetically anchored drug target discovery for neglected diseases
GenDrug aims to develop innovative algorithms integrating genomic and real-world data to identify drug targets and accelerate drug development for neglected non-communicable diseases.
Developing a human-based stem cell model for reproductive toxicity
Developing a high-throughput human-based assay for male reproductive toxicity to enhance drug safety testing and reduce reliance on animal models.
Revolutionizing AI in drug discovery via innovative molecular representation paradigms
ReMINDER aims to revolutionize drug discovery by developing novel molecular representations for AI, enhancing model capabilities and solving complex chemical challenges.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Drug Discovery IntelligenceHet project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties. | Mkb-innovati... | € 20.000 | 2020 | Details |
QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors and Artificial IntelligenceThis project aims to revolutionize computational toxicology by developing interpretable quantum mechanics-based descriptors (ESigns) for accurate toxicity predictions across the entire chemical space. | EIC Pathfinder | € 1.994.770 | 2024 | Details |
AI to render the best clinical trial design for a novel RNA therapy.Het ANTENA-project ontwikkelt een AI-platform om de optimale klinische studiepopulatie voor een nieuwe RNA-medicatie te identificeren, met als doel kosten en risico's van klinische proeven te verlagen. | Mkb-innovati... | € 199.700 | 2023 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Universal GPCR Activity Sensor for Next Generation Drug DiscoveryThis project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures. | EIC Pathfinder | € 2.965.384 | 2023 | Details |
Drug Discovery Intelligence
Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.
QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors and Artificial Intelligence
This project aims to revolutionize computational toxicology by developing interpretable quantum mechanics-based descriptors (ESigns) for accurate toxicity predictions across the entire chemical space.
AI to render the best clinical trial design for a novel RNA therapy.
Het ANTENA-project ontwikkelt een AI-platform om de optimale klinische studiepopulatie voor een nieuwe RNA-medicatie te identificeren, met als doel kosten en risico's van klinische proeven te verlagen.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Universal GPCR Activity Sensor for Next Generation Drug Discovery
This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.